Approved: Sorafenib and Lenvatinib for the Treatment of Progressive, RAI-­Refractory DTC

Approved: Sorafenib and Lenvatinib for the Treatment of Progressive, RAI-­Refractory DTC

In this first of two videos on the refractory thyroid cancer, Marcia Brose, MD, discusses the approved multi­kinase inhibitors sorafenib and lenvatinib for progressive, RAI­-refractory differentiated thyroid cancer. Dr. Brose played a key role in the approval of sorafenib for thyroid cancer in 2013, and is widely considered a leading expert in the treatment of refractory thyroid cancer.

View the 2016 update on this topic here

 

 

 

Related Links


Published

September 23, 2015

Created by

Penn Physician VideoLink